John M. Varlotto, MD, on Concurrent and Consolidation Durvalumab for Unresectable Stage III NSCLC

September 10, 2025 By The ASCO Post Staff

John M. Varlotto, MD, presents results from the phase III EA5181 trial (from the ECOG-ACRIN Cancer Research Group), which evaluated concurrent and consolidation durvalumab vs consolidation durvalumab alone for patients with unresectable stage III non–small cell lung cancer (NSCLC) (Abstract PL03.04). 

Related Content